Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VERU
VERU logo

VERU Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Veru Inc (VERU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.130
1 Day change
52 Week Range
7.400
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Veru Inc (VERU) is not a good buy for a beginner, long-term investor at this moment. The technical indicators are bearish, options data shows weak sentiment, and the company's financial performance is declining. With no positive news or catalysts, the stock does not align with the user's investment goals.

Technical Analysis

The technical indicators for VERU are bearish. The MACD is negatively expanding, RSI is neutral at 23.109, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 2.218 and resistance at 2.432.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The low put-call ratio in open interest suggests minimal hedging activity, while the higher option volume put-call ratio indicates bearish sentiment among traders.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
4

Positive Catalysts

  • NULL. There are no significant positive news, insider activity, hedge fund trends, or congress trading data to act as catalysts.

Neutral/Negative Catalysts

  • The company's financial performance is deteriorating, with a 40.39% YoY drop in net income and a 57.38% YoY drop in EPS. Technical indicators are bearish, and there is no positive news or sentiment to support a buy decision.

Financial Performance

In Q1 2026, Veru Inc reported no revenue growth (0% YoY), a significant drop in net income (-40.39% YoY), and a sharp decline in EPS (-57.38% YoY). Gross margin remained flat at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for VERU.

Wall Street analysts forecast VERU stock price to rise
1 Analyst Rating
Wall Street analysts forecast VERU stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.130
sliders
Low
25
Averages
25
High
25
Current: 2.130
sliders
Low
25
Averages
25
High
25
Canaccord
NULL -> Buy
initiated
$25
AI Analysis
2025-12-18
Reason
Canaccord
Price Target
$25
AI Analysis
2025-12-18
initiated
NULL -> Buy
Reason
Canaccord initiated coverage of Veru with a Buy rating and $25 price target. Veru is positioned as a differentiated biotech in obesity drug development, with lead candidate enobosarm, an oral selective androgen receptor agonist, being evaluated in Phase IIb alongside a GLP-1 receptor agonist to preserve muscle during weight loss, the analyst tells investors in a research note. A second Phase IIb trial is planned for 1Q26, with top-line data expected in 1H28, the firm says.

People Also Watch